Instil Bio, Inc. reported a net loss of $4.3 million for the three months ended June 30, 2026, a significant improvement compared to a net loss of $21.4 million for the same period in 2025. For the six months ended June 30, 2026, the company recorded a net loss of $8.5 million, down from $49.6 million in the prior year. The reduction in losses is attributed to a decrease in operating expenses, which totaled $5.6 million for the second quarter of 2026, compared to $23.4 million in the same quarter of 2025. The company’s accumulated deficit as of June 30, 2026, stood at $735 million, with total current assets decreasing to $71.6 million from $191.4 million at the end of 2025.
The company experienced a notable decline in research and development expenses, which fell to $0.3 million in the second quarter of 2026 from $6.7 million in the same quarter of 2025. This decrease was primarily due to the discontinuation of the AXN-2510 development program. General and administrative expenses also decreased to $5.1 million from $6.2 million year-over-year, reflecting cost-cutting measures. The restructuring and impairment charges were significantly lower at $0.2 million for the second quarter of 2026, compared to $0.5 million in the same period of 2025.
In terms of operational developments, Instil Bio's wholly owned subsidiary, Axion Bio, discontinued the development of AXN-2510 in January 2026. The company is actively seeking to in-license or acquire new therapeutic candidates to address unmet medical needs. Additionally, the company reclassified its Tarzana facility from held for sale to held and used in May 2026, resulting in a net remeasurement loss of $0.2 million. The facility is now valued at $111.7 million, reflecting adjustments for depreciation and impairment.
As of June 30, 2026, Instil Bio had cash, cash equivalents, restricted cash, and marketable securities totaling $69.9 million, which included $5.5 million in cash and cash equivalents and $64.1 million in marketable securities. The company has indicated that it expects to continue incurring net losses for the foreseeable future. To address its financial obligations, including a loan of $85.6 million due in January 2027, the company plans to exercise its option to extend the loan's maturity to January 2028. Instil Bio may also consider refinancing the loan, selling the Tarzana facility, or seeking additional financing through equity or debt instruments.
About Instil Bio, Inc.
Instil Bio, Inc. is a biopharmaceutical company focused on developing novel immunotherapies for cancer. Its pipeline includes bispecific antibodies targeting PD-L1 and VEGF, as well as other immune-modulating agents. The company collaborates globally, advancing clinical trials for solid tumor treatments, and aims to commercialize approved therapies. Its core strengths lie in innovative biologic platforms, strategic licensing, and a focus on unmet medical needs in oncology.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov